Treatment with CGM097 at 100 mg/kg in SJSA-1 tumour-bearing mice showed that the unbound drug concentration in plasma (plasma protein binding = 99.8% in mouse) stayed above the in vitro biochemical inhibitory concentration 90% (IC90) (14 nM) for the first 24 h17 and such sustained exposure highly induced p21 (maximum effect Emax = 41-fold) and PUMA, (Emax = 19-fold) (Fig. 1b). The gene discussed is CDKN1A; the disease is neoplasm.